CoLucid Pharmaceuticals Garners $37,100,000 Series C Funding

  • Feed Type
  • Date
    1/13/2015
  • Company Name
    CoLucid Pharmaceuticals
  • Mailing Address
    P.O. Box 14401 Durham, NC 27709 USA
  • Company Description
    CoLucid Pharmaceuticals is an innovative biotechnology company focusing on therapies for central nervous system (CNS) disorders. CoLucid is leading a paradigm shift in migraine therapy with the clinical development of a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA).
  • Website
    http://www.colucid.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $37,100,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the Series C will be used to fund the Company’s Phase 3 program for oral Lasmiditan, to include the first pivotal study, COL MIG-301 SAMURAI, for the acute treatment of migraine.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy